{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:12:45Z","timestamp":1781651565886,"version":"3.54.5"},"reference-count":75,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["12\/35\/64 EudraCT number 2014-002193-37, REC 14\/LNO\/1428, IRAS 156358, Local R&D registration CHAD 1031"],"award-info":[{"award-number":["12\/35\/64 EudraCT number 2014-002193-37, REC 14\/LNO\/1428, IRAS 156358, Local R&D registration CHAD 1031"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012068","name":"Health and Care Research Wales","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012068","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>In the United Kingdom, it is estimated that 5,000 patients sustain eye injuries or ocular trauma requiring hospital admission annually, of which 250 patients will be permanently blinded. This study explores the cost-effectiveness of Adjunctive Steroid Combination in Ocular Trauma (ASCOT) given during surgery versus standard treatment in vitreoretinal surgery in patients with open globe trauma.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>This economic evaluation was embedded alongside the ASCOT RCT (ClinicalTrials.gov Identifier: NCT02873026). We conducted a primary cost-effectiveness analysis from a National Health Service perspective using the proportion of patients who achieved a visual acuity of 10 or more letter improvement on the Early Treatment Diabetic Retinopathy Study (ETDRS) scale as the measure of effect, in developing incremental cost-effectiveness ratios (ICERs). Secondary cost-utility analysis using the EuroQol 5 Dimension 5 Level (EQ-5D-5L) to generate a cost per quality-adjusted life-year (QALY), and a cost-effectiveness analysis using vision-specific quality of life (QoL) was conducted. Sensitivity analyses were also applied to investigate parameter uncertainties.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>The sample size of the ASCOT intervention arm and standard care arm of this study was 130 and 129, respectively. The intervention cost per patient was estimated at \u00a3132. The proportion of participants with an ETDRS of 10 or more letter improvement was 0.47 for the ASCOT group with a mean cost of \u00a35,526 per patient, while the standard care group had an effect of 0.43 with a mean cost of \u00a35,099 per patient. The ICER value of the primary outcome was \u00a312,178 per 10 or more letter improvement on the ETDRS score. The secondary result in terms of cost per QALYs gained had a probability of 44% being cost-effective at a willingness-to-pay threshold of \u00a330,000\/QALY gained.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Though there is no formally accepted cost-effectiveness willingness-to-pay threshold for 10-letter or more improvement, the ASCOT intervention for open globe trauma is a low-cost intervention. The ASCOT intervention is not cost-effective when compared to the standard care in this group and setting. The proportion of patients in the ASCOT intervention arm with 10 or more letter improvement produced some positive results but this is outweighed by the costs.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0311158","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T18:29:11Z","timestamp":1734373751000},"page":"e0311158","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Economic evaluation of an adjunctive intraocular and peri-ocular steroid vitreoretinal surgery for open globe trauma: Cost-effectiveness of the ASCOT randomised controlled trial"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4211-8942","authenticated-orcid":true,"given":"Victory \u2018Segun","family":"Ezeofor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany F.","family":"Anthony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Bryning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J.","family":"Casswell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzie","family":"Cro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria R.","family":"Cornelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catey","family":"Bunce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Charteris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhiannon Tudor","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"issue":"12 Suppl","key":"pone.0311158.ref001","first-page":"S1","article-title":"Injuries as a public health problem in sub-Saharan Africa: epidemiology and prospects for control","volume":"77","author":"E. Nordberg","year":"2000","journal-title":"East African medical journal"},{"issue":"3","key":"pone.0311158.ref002","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1076\/opep.5.3.143.8364","article-title":"The global impact of eye injuries.","volume":"5","author":"AD N\u00e9grel","year":"1998","journal-title":"Ophthalmic epidemiology."},{"issue":"2","key":"pone.0311158.ref003","doi-asserted-by":"crossref","DOI":"10.5812\/atr.21639","article-title":"Ocular trauma: an overview","volume":"3","author":"D. Aghadoost","year":"2014","journal-title":"Archives of Trauma Research,."},{"issue":"7","key":"pone.0311158.ref004","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1136\/bjo.80.7.592","article-title":"Incidence of cases of ocular trauma admitted to hospital and incidence of blinding outcome","volume":"80","author":"P Desai","year":"1996","journal-title":"British journal of ophthalmology"},{"issue":"5","key":"pone.0311158.ref005","first-page":"738","article-title":"Ocular trauma treated with pars plana vitrectomy: early outcome report.","volume":"9","author":"MR Mansouri","year":"2016","journal-title":"International journal of ophthalmology"},{"issue":"6","key":"pone.0311158.ref006","first-page":"829","article-title":"Ocular emergencies.","volume":"76","author":"PK Pokhrel","year":"2007","journal-title":"American family physician"},{"issue":"2","key":"pone.0311158.ref007","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ajo.2010.02.015","article-title":"Characteristics and outcomes of work-related open globe injuries","volume":"150","author":"JM Kanoff","year":"2010","journal-title":"American journal of ophthalmology"},{"issue":"21","key":"pone.0311158.ref008","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/j.jcin.2016.08.010","article-title":"Comparative Assessment of Procedure Cost and Outcomes Between Guidewire and Crossing Device Strategies to Cross Peripheral Artery Chronic Total Occlusions.","volume":"9","author":"S Banerjee","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"issue":"3","key":"pone.0311158.ref009","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S0161-6420(88)33183-0","article-title":"The spectrum and burden of ocular injury","volume":"95","author":"OD Schein","year":"1988","journal-title":"Ophthalmology"},{"issue":"10","key":"pone.0311158.ref010","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.3390\/diagnostics11101851","article-title":"Open globe injuries: classifications and prognostic factors for functional outcome.","volume":"11","author":"CS Mayer","year":"2021","journal-title":"Diagnostics"},{"key":"pone.0311158.ref011","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ajo.2021.08.003","article-title":"Global current practice patterns for the management of open globe injuries","volume":"234","author":"SC Miller","year":"2022","journal-title":"American journal of ophthalmology"},{"issue":"7","key":"pone.0311158.ref012","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/S0161-6420(97)30167-5","article-title":"Post-traumatic proliferative Vitreoretinopathy: the Epidemiologfic profile, onset, risk factors, and visual outcome","volume":"104","author":"JA Cardillo","year":"1997","journal-title":"Ophthalmology"},{"issue":"2","key":"pone.0311158.ref013","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/0002-9394(81)90171-9","article-title":"Glucocorticosteroid inhibition of intraocular proliferation after injury.","volume":"91","author":"Y Tano","year":"1981","journal-title":"American journal of ophthalmology [Internet]."},{"issue":"6","key":"pone.0311158.ref014","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0002-9394(14)75196-7","article-title":"Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide","volume":"90","author":"Y Tano","year":"1980","journal-title":"American journal of ophthalmology [Internet]."},{"issue":"1","key":"pone.0311158.ref015","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/00006982-199701000-00009","article-title":"Therapeutic effect of periocular corticosteroids in experimental proliferative vltreoretinopathy.","volume":"17","author":"PE Rubsamen","year":"1997","journal-title":"Retina [Internet]."},{"issue":"7","key":"pone.0311158.ref016","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1136\/bjophthalmol-2015-307347","article-title":"Triamcinolone during pars plana vitrectomy for open globe trauma: a pilot randomised controlled clinical trial","volume":"100","author":"PJ Banerjee","year":"2016","journal-title":"British Journal of Ophthalmology [Internet]."},{"issue":"6","key":"pone.0311158.ref017","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ophtha.2017.01.021","article-title":"Slow-release dexamethasone in proliferative vitreoretinopathy: a prospective, randomized controlled clinical trial","volume":"124","author":"PJ Banerjee","year":"2017","journal-title":"Ophthalmology [Internet]."},{"issue":"7","key":"pone.0311158.ref018","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s00417-011-1919-y","article-title":"Systemic corticosteroids reduce the risk of cellophane membranes after retinal detachment surgery: a prospective randomized placebo-controlled double-blind clinical trial","volume":"250","author":"F Koerner","year":"2012","journal-title":"Graefes Arch Clin Exp Ophthalmol [Internet]."},{"key":"pone.0311158.ref019","article-title":"Randomised controlled trial of adjunctive triamcinolone acetonide in eyes undergoing vitreoretinal surgery following open globe trauma: The ASCOT study","author":"EJ Casswell","year":"2023","journal-title":"British Journal of Ophthalmology"},{"key":"pone.0311158.ref020","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.2147\/OPTH.S59776","article-title":"Intracameral cefuroxime and moxifloxacin used as endophthalmitis prophylaxis after cataract surgery: systematic review of effectiveness and cost-effectiveness.","author":"R Linertov\u00e1","year":"2014","journal-title":"Clinical Ophthalmology"},{"issue":"9","key":"pone.0311158.ref021","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/ceo.12789","article-title":"Efficacy and cost-effectiveness of intracameral vancomycin in reducing postoperative endophthalmitis incidence in Australia.","volume":"44","author":"CP Au","year":"2016","journal-title":"Clinical & Experimental Ophthalmology."},{"issue":"1","key":"pone.0311158.ref022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12913-018-3804-4","article-title":"Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN\u00ae) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies.","volume":"19","author":"M Pochopien","year":"2019","journal-title":"BMC Health Services Research"},{"key":"pone.0311158.ref023","first-page":"1","article-title":"A phase III, multi-centre, double-masked randomised controlled trial of adjunctive intraocular and peri-ocular steroid (triamcinolone acetonide) versus standard treatment in eyes undergoing vitreoretinal surgery for open globe trauma (ASCOT): statistical analysis plan.","volume":"17","author":"JW Lo","year":"2016","journal-title":"Trials"},{"key":"pone.0311158.ref024","first-page":"311","article-title":"Prospective evaluation of visual acuity assessment: a comparison of snellen versus ETDRS charts in clinical practice (An AOS Thesis).","volume":"107","author":"PK Kaiser","year":"2009","journal-title":"Transactions of the American Ophthalmological Society"},{"issue":"12","key":"pone.0311158.ref025","first-page":"1","article-title":"A randomised controlled trial of adjunctive triamcinolone acetonide in eyes undergoing vitreoretinal surgery for open globe trauma-the ASCOT study","volume":"27","author":"DG Charteris","year":"2023","journal-title":"Health Technology Assessment (Winchester, England) [Internet]."},{"key":"pone.0311158.ref026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13063-016-1445-7","article-title":"Adjunctive intraocular and peri-ocular steroid (triamcinolone acetonide) versus standard treatment in eyes undergoing vitreoretinal surgery for open globe trauma (ASCOT): study protocol for a phase III, multi-centre, double-masked randomised controlled trial.","volume":"17","author":"PJ Banerjee","year":"2016","journal-title":"Trials"},{"key":"pone.0311158.ref027","volume-title":"Incorporating economic evaluation | Developing NICE guidelines: the manual | Guidance | NICE | Last updated: 17 January 2024 [Internet].","author":"NICE","year":"2014"},{"key":"pone.0311158.ref028","volume-title":"Economic evaluation | NICE health technology evaluations: the manual | Guidance | NICE [Internet]","year":"2022"},{"key":"pone.0311158.ref029","volume-title":"Methods for the economic evaluation of health care programmes","author":"MF Drummond","year":"2015"},{"key":"pone.0311158.ref030","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/med\/9780198737483.001.0001","volume-title":"Applied Health Economics for Public Health Practice and Research","author":"RT Edwards","year":"2019"},{"key":"pone.0311158.ref031","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40273-015-0371-y","article-title":"Conducting economic evaluations alongside randomised trials: current methodological issues and novel approaches.","volume":"34","author":"D Hughes","year":"2016","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"pone.0311158.ref032","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/hec.3029","article-title":"Taxonomy for methods of resource use measurement","volume":"24","author":"CH Ridyard","year":"2015","journal-title":"Health Economics"},{"key":"pone.0311158.ref033","article-title":"Prescription Cost Analysis\u2014England 2019. NHSBSA Statistics","author":"NHSBSA","year":"2019","journal-title":"NHS Business Service Authority. [Internet]"},{"key":"pone.0311158.ref034","author":"KC Jones","year":"2022","journal-title":"Unit Costs of Health and Social Care 2022 Manual"},{"key":"pone.0311158.ref035","author":"NHS England.","journal-title":"2021\/22 National Cost Collection Data Publication [Internet]."},{"issue":"6","key":"pone.0311158.ref036","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/00006982-200412000-00007","article-title":"Resources involved in managing retinal detachment complicated by proliferative vitreoretinopathy","volume":"24","author":"NN Patel","year":"2004","journal-title":"Retina [Internet]."},{"issue":"7","key":"pone.0311158.ref037","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0161-6420(01)00589-9","article-title":"Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: results from a randomized, double-blind, controlled clinical trial","volume":"108","author":"RHY Asaria","year":"2001","journal-title":"Ophthalmology [Internet]."},{"issue":"4","key":"pone.0311158.ref038","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.ophtha.2006.08.042","article-title":"Randomized controlled trial of combined 5-Fluorouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy","volume":"114","author":"L Wickham","year":"2007","journal-title":"Ophthalmology [Internet]."},{"issue":"12","key":"pone.0311158.ref039","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1016\/j.ophtha.2004.05.036","article-title":"A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy","volume":"111","author":"DG Charteris","year":"2004","journal-title":"Ophthalmology [Internet]."},{"issue":"2","key":"pone.0311158.ref040","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1517\/14740338.2012.635141","article-title":"Drug safety evaluation of intravitreal triamcinolone acetonide","volume":"11","author":"D Veritti","year":"2012","journal-title":"Expert Opinion on Drug Safety [Internet]."},{"issue":"5","key":"pone.0311158.ref041","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3928\/15428877-20070901-02","article-title":"Triamcinolone Acetonide as an Adjuvant in the Surgical Treatment of Retinal Detachment With Proliferative Vitreoretinopathy","volume":"38","author":"RA Cheema","year":"2007","journal-title":"Ophthalmic Surg Lasers Imaging Retina [Internet]."},{"issue":"5","key":"pone.0311158.ref042","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S0008-4182(05)80052-3","article-title":"Intravitreal triamcinolone for treatment of complicated proliferative diabetic retinopathy and proliferative vitreoretinopathy.","volume":"40","author":"WM Munir","year":"2005","journal-title":"Canadian journal of ophthalmology [Internet]."},{"issue":"8","key":"pone.0311158.ref043","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/BF00184858","article-title":"Does the presence of heparin and dexamethasone in the vitrectomy infusate reduce reproliferation in proliferative vitreoretinopathy?","volume":"234","author":"RG Williams","year":"1996","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol [Internet]."},{"issue":"6","key":"pone.0311158.ref044","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/BF00231411","article-title":"Postoperative retinal fibrosis\u2014a controlled clinical study of systemic steroid therapy","volume":"219","author":"F Koerner","year":"1982","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol [Internet]."},{"issue":"3","key":"pone.0311158.ref045","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0161-6420(88)33181-7","article-title":"A prospective, randomized, clinical trial of heparin therapy for postoperative intraocular fibrin","volume":"95","author":"RN Johnson","year":"1988","journal-title":"Ophthalmology [Internet]."},{"key":"pone.0311158.ref046","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s11136-012-0322-4","article-title":"Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study.","volume":"22","author":"MF Janssen","year":"2013","journal-title":"Quality of life research."},{"key":"pone.0311158.ref047","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40258-017-0310-5","article-title":"EQ-5D and the EuroQol group: past, present and future","volume":"15","author":"NJ Devlin","year":"2017","journal-title":"Applied health economics and health policy"},{"key":"pone.0311158.ref048","unstructured":"EQ-5D [Internet]. [cited 2023 Apr 17]. Available from: https:\/\/euroqol.org\/."},{"issue":"6","key":"pone.0311158.ref049","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1167\/iovs.10-5645","article-title":"Validation of the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) in age-related macular degeneration.","volume":"52","author":"P Orr","year":"2011","journal-title":"Investigative ophthalmology & visual science"},{"key":"pone.0311158.ref050","unstructured":"Visual Function Questionnaire 25 | National Eye Institute [Internet]. [cited 2023 Apr 17]. Available from: https:\/\/www.nei.nih.gov\/learn-about-eye-health\/outreach-campaigns-and-resources\/outreach-materials\/visual-function-questionnaire-25."},{"issue":"5","key":"pone.0311158.ref051","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/hec.944","article-title":"Estimating mean QALYs in trial\u2010based cost\u2010effectiveness analysis: the importance of controlling for baseline utility","volume":"14","author":"A Manca","year":"2005","journal-title":"Health Economics [Internet]."},{"key":"pone.0311158.ref052","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.chemolab.2014.02.007","article-title":"A practical comparison of single and multiple imputation methods to handle complex missing data in air quality datasets.","volume":"134","author":"MP G\u00f3mez-Carracedo","year":"2014","journal-title":"Chemometrics and Intelligent Laboratory Systems [Internet]."},{"key":"pone.0311158.ref053","volume-title":"Statistical analysis with missing data","author":"RJ Little","year":"2019"},{"issue":"24","key":"pone.0311158.ref054","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1002\/sim.1391","article-title":"Use of the mean, hot deck and multiple imputation techniques to predict outcome in intensive care unit patients in Colombia.","volume":"21","author":"A Perez","year":"2002","journal-title":"Statistics in medicine."},{"issue":"29","key":"pone.0311158.ref055","first-page":"iii","article-title":"Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making.","volume":"13","author":"L Andronis","year":"2009","journal-title":"Health technology assessment (Winchester, England)."},{"key":"pone.0311158.ref056","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision Modelling for Health Economic Evaluation","author":"AH Briggs","year":"2006"},{"key":"pone.0311158.ref057","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-15744-3","volume-title":"Cost effectiveness modelling for health technology assessment: a practical course","author":"R Edlin","year":"2015"},{"issue":"9","key":"pone.0311158.ref058","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2165\/00019053-200826090-00004","article-title":"The NICE Cost-Effectiveness Threshold","volume":"26","author":"C McCabe","year":"2008","journal-title":"Pharmacoeconomics [Internet]."},{"key":"pone.0311158.ref059","article-title":"Developing NICE guidelines: the manual.","author":"NICE","year":"2022","journal-title":"Process and methods [Internet]."},{"issue":"5","key":"pone.0311158.ref060","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40273-017-0606-1","article-title":"Cost-Effectiveness Thresholds: the Past, the Present and the Future","volume":"36","author":"P Thokala","year":"2018","journal-title":"PharmacoEconomics [Internet]."},{"issue":"5","key":"pone.0311158.ref061","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jval.2016.02.020","article-title":"On the Estimation of the Cost-Effectiveness Threshold: Why, What, How?","volume":"19","author":"L Vallejo-Torres","year":"2016","journal-title":"Value in Health [Internet]."},{"issue":"8","key":"pone.0311158.ref062","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s40273-020-00914-6","article-title":"Calculating and Interpreting ICERs and Net Benefit.","volume":"38","author":"M Paulden","year":"2020","journal-title":"PharmacoEconomics [Internet]."},{"issue":"1","key":"pone.0311158.ref063","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1146\/annurev.publhealth.23.100901.140534","article-title":"Thinking Outside the Box: Recent Advances in the Analysis and Presentation of Uncertainty in Cost-Effectiveness Studies","volume":"23","author":"AH Briggs","year":"2002","journal-title":"Annu Rev Public Health [Internet]."},{"issue":"2","key":"pone.0311158.ref064","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1017\/S0266462313000160","article-title":"Consolidated health economic evaluation reporting standards (CHEERS) statement.","volume":"29","author":"D Husereau","year":"2013","journal-title":"International journal of technology assessment in health care"},{"issue":"1","key":"pone.0311158.ref065","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jval.2021.10.008","article-title":"Consolidated health economic evaluation reporting standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II Good Practices Task Force.","volume":"25","author":"D Husereau","year":"2022","journal-title":"Value in Health"},{"key":"pone.0311158.ref066","author":"NICE, Process and methods","year":"2013","journal-title":"Guide to the methods of technology appraisal 2013."},{"key":"pone.0311158.ref067","author":"Medical forms","journal-title":"Medicinal forms | Triamcinolone acetonide | Drugs | BNF content published by NICE [Internet]."},{"issue":"31","key":"pone.0311158.ref068","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta23310","article-title":"Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT","volume":"23","author":"G Gazzard","year":"2019","journal-title":"Health Technology Assessment (Winchester, England)."},{"issue":"3","key":"pone.0311158.ref069","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1525-1446.1992.tb00095.x","article-title":"Secondary Data on Health-Related Subjects: Major Sources, Uses, and Limitations.","volume":"9","author":"JS Brown","year":"1992","journal-title":"Public Health Nursing."},{"key":"pone.0311158.ref070","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4135\/9781529682762.n8","article-title":"Complexities of working with secondary data: Limitations of archival and secondary data analysis","author":"T. Chandola","year":"2021","journal-title":"Archival and secondary data."},{"issue":"6","key":"pone.0311158.ref071","article-title":"Adjunctive steroid therapy versus antibiotics alone for acute endophthalmitis after intraocular procedure.","author":"S Emami","year":"2022","journal-title":"Cochrane Database of Systematic Reviews."},{"issue":"4","key":"pone.0311158.ref072","doi-asserted-by":"crossref","first-page":"169","DOI":"10.4274\/tjo.88785","article-title":"The effect of adjuvant intracameral triamcinolone acetonide on the surgical results of trabeculectomy with mitomycin C","volume":"46","author":"N Alag\u00f6z","year":"2016","journal-title":"Turkish Journal of Ophthalmology"},{"issue":"6","key":"pone.0311158.ref073","first-page":"384","article-title":"Treatment of oedematous, proliferative and neovascular diseases by intravitreal triamcinolone acetonide.","volume":"220","author":"JB Jonas","year":"2003","journal-title":"Klinische Monatsblatter fur Augenheilkunde"},{"issue":"2","key":"pone.0311158.ref074","first-page":"113","article-title":"Intravitreal triamcinolone acetonide for the treatment of intraocular edematous and neovascular diseases.","volume":"101","author":"JB Jonas","year":"2004","journal-title":"Der Ophthalmologe: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft."},{"issue":"8","key":"pone.0311158.ref075","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/s41433-019-0408-0","article-title":"Intraocular application of Mitomycin C to prevent proliferative vitreoretinopathy in perforating and severe intraocular foreign body injuries.","volume":"33","author":"A Assi","year":"2019","journal-title":"Eye"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0311158","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T18:29:34Z","timestamp":1734373774000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0311158"}},"subtitle":[],"editor":[{"given":"Daisuke","family":"Nagasato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,12,16]]},"references-count":75,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0311158","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,16]]}}}